What is he best known for?
The fields of study he is best known for:
Yi Zheng mostly deals with Cell biology, RAC1, RHOA, CDC42 and GTPase.
His Cdc42 GTP-Binding Protein, Progenitor cell, Signal transduction, Stem cell and Intracellular investigations are all subjects of Cell biology research.
His work carried out in the field of Stem cell brings together such families of science as Immunology and Adult stem cell.
His RAC1 research focuses on Cell growth and how it connects with Gene targeting, Autocrine signalling, Cytoskeleton organization and Cytoskeleton.
His RHOA research is multidisciplinary, relying on both Carcinogenesis, Cancer, Morphogenesis, Stress fiber and Small molecule.
His CDC42 study frequently draws connections to other fields, such as Cancer research.
His most cited work include:
- Rational design and characterization of a Rac GTPase-specific small molecule inhibitor (947 citations)
- Rho GTPase-activating proteins in cell regulation (521 citations)
- CDC42 ACTIVITY REGULATES HEMATOPOIETIC STEM CELL AGING AND REJUVENATION (316 citations)
What are the main themes of his work throughout his whole career to date?
Yi Zheng mainly focuses on Cell biology, Cancer research, RHOA, Stem cell and CDC42.
RAC1, GTPase, Progenitor cell, Cdc42 GTP-Binding Protein and Signal transduction are among the areas of Cell biology where the researcher is concentrating his efforts.
His work deals with themes such as Carcinogenesis, Cancer, Cell cycle, Cell growth and Leukemia, which intersect with Cancer research.
His RHOA study integrates concerns from other disciplines, such as Molecular biology, Actin cytoskeleton and Cytokinesis.
His Stem cell research includes themes of Endothelial stem cell and Transplantation.
His Haematopoiesis research is multidisciplinary, incorporating perspectives in Erythropoiesis and Bone marrow.
He most often published in these fields:
- Cell biology (58.60%)
- Cancer research (24.19%)
- RHOA (19.53%)
What were the highlights of his more recent work (between 2016-2021)?
- Cell biology (58.60%)
- Cancer research (24.19%)
- Haematopoiesis (16.74%)
In recent papers he was focusing on the following fields of study:
Cell biology, Cancer research, Haematopoiesis, Stem cell and CDC42 are his primary areas of study.
His Cell biology study combines topics in areas such as Chromatin, Leukemia and Epigenetics.
His Cancer research study incorporates themes from Cancer, Cellular differentiation, RUNX1, STAT3 and RHOA.
His work in RHOA addresses subjects such as GTPase, which are connected to disciplines such as RAC1.
Yi Zheng has included themes like Phenotype and Ex vivo in his Stem cell study.
His CDC42 research incorporates elements of Endothelial stem cell, Angiogenesis, Regeneration and Cell polarity.
Between 2016 and 2021, his most popular works were:
- Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV. (85 citations)
- YAP/TAZ-CDC42 signaling regulates vascular tip cell migration (77 citations)
- YAP/TAZ-CDC42 signaling regulates vascular tip cell migration (77 citations)
In his most recent research, the most cited papers focused on:
His main research concerns Cell biology, Cancer research, Progenitor cell, Signal transduction and Angiogenesis.
His is doing research in CDC42, Stem cell, RHOA, RAC1 and GTPase, both of which are found in Cell biology.
His studies in Stem cell integrate themes in fields like Chromatin, Cytokine, Bone marrow and CXCR4.
His biological study spans a wide range of topics, including Genotype-phenotype distinction, Leukemia and Growth factor receptor.
His research in Progenitor cell intersects with topics in Haematopoiesis, Hematopoietic stem cell, Cell signaling, Inflammation and Innate immune system.
His Angiogenesis research is multidisciplinary, incorporating elements of GATA4, Mice transgenic, Myocardial infarction and Regeneration.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
